World’s largest society for regulatory professionals increases investment in Europe
An investment of more than 2 million euro over 3 years is planned to launch new events and resources.
The Regulatory Affairs Professionals Society (RAPS) is stepping up its presence in Europe and expanding its European team in response to growing membership demand from those involved with the regulation of healthcare and related products.
In the last 12 months, the largest global organisation for regulatory professionals in the healthcare, medical device, biologic and pharmaceutical sectors has seen its European member base grow by approximately 19% to more than 1,500 members across 29 countries.
RAPS plans to invest more than 2 million euro over 3 years implementing a strategic growth plan in Europe that includes launching new events and resources to serve the needs of regulatory professionals in the region.
RAPS executive director Paul Brooks said: “Europe has a vibrant and progressive healthcare products community and many of our existing regulatory professionals are working here, so increasing our investment in Europe was a natural next step for RAPS.
“Healthcare is a global business, and with more than 15,000 members in over 80 countries, we are well aware of the challenges regulatory professionals face worldwide. Our own research has shown that in Europe more than 65% of professionals in the healthcare product industries have multi-regional or worldwide responsibilities,” said Brooks. “RAPS is committed to understanding the specific needs of European regulatory professionals and supporting our local chapters and networks.”
The investment program includes a substantial increase in staff resources for European members and a series of European events including a RAPS Roadshow: ‘Examining the New European Medical Device Regulations’ on 4 May in Munich and a workshop ‘EU Regulatory Essentials, Medical Device and In Vitro Diagnostics: Transitioning from Current Directives to New Regulations’ on 4 and 5 July in Brussels.
Brooks continued: “In highly regulated environments such as the pharmaceutical and medical device sectors, there is a greater need than ever for regulatory professionals to stay up to date on the latest regulatory developments. In particular, changes to medical device regulations in Europe present a huge challenge to manufacturers and should be high on the industry’s agenda as we move towards the 2020 deadline.”
In addition to in-person events, RAPS will host a four-part virtual programme in May, ‘Understanding the New EU Medical Device and IVD Regulations’ and has produced a helpful ‘interactive guide’ to the new EU Medical Device and IVD Regulations.
As part of its investment in Europe RAPS is also looking to increase awareness of its Regulatory Affairs Certification (RAC). The RAC is the only professional certification specifically for those in the healthcare product regulatory field, testing knowledge and critical thinking relating to the international practice of regulatory affairs. Four RAC credentials are available, including one focused on European regulations. Currently, more than 4,000 individuals around the world are RAC-credentialed.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance